Shares of Adamas Pharmaceuticals ADMS rose in after-market trading after the company reported Q4 results.
Quarterly Results
Earnings per share rose 22.89% over the past year to ($0.64), which missed the estimate of ($0.51).
Revenue of $21,010,000 rose by 28.52% from the same period last year, which beat the estimate of $20,960,000.
Looking Ahead
Adamas Pharmaceuticals Sees FY 2021 Total Operating Expenses Expenses $115M-$130M
How To Listen To The Conference Call
Date: Feb 23, 2021
Time: 04:30 PM
ET Webcast URL: https://edge.media-server.com/mmc/p/9kbxdi2b
Technicals
52-week high: $9.15
Company's 52-week low was at $1.90
Price action over last quarter: Up 49.86%
Company Profile
Adamas Pharmaceuticals Inc discovers, develops, and sells therapies for chronic neurologic disorders. The company's approved/commercial product is GOCOVRI, an amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease. It operates in one reportable segment: the development and commercialization of therapeutics targeting chronic disorders of the central nervous system. The company generates its revenues primarily from the United States.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.